Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 19 June 2018

Indication(s)

- PritorPlus 40 mg/12.5 mg tablets
- PritorPlus 80 mg/12.5 mg tablets

Treatment of essential hypertension.

PritorPlus fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide and 80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.
 

- PritorPlus 80 mg/25 mg tablets

Treatment of essential hypertension.

PritorPlus fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on PritorPlus 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Load more

Related Content

Journal articles

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update -2016.

True resistant hypertension must be distinguished from apparent resistant hypertension, of which important causes include medication nonadherence, illicit drug use...

Added 3 years ago

Obesity and prevalence of cardiovascular diseases and prognosis:the obesity paradox updated.

The prevalence and severity of obesity has increased in the United States and most of the Westernized World over recent...

Added 3 years ago

Overview of epidemiology and contribution of obesity to cardiovascular disease.

The prevalence of obesity has increased worldwide and is a source of concern since the negative consequences of obesity start...

Added 5 years ago

Load more

View all 13128 Journal articles items
Guidelines

2013 ESH/ESC Guidelines for the management of arterial hypertension

The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) follow the guidelines jointly issued by the two societies in 2003 and 2007.

Added 5 years ago

KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease aims to provide guidance on blood pressure management and treatment for...

Added 6 years ago

Hypertension in adults: diagnosis and management

This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over.

Added 7 years ago

Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension

Obese patients are prone to arterial hypertension, require more antihypertensive medications, and have an increased risk of treatment-resistant arterial hypertension.

Added 7 years ago

Load more

View all 1443 Guidelines items

More information

Category Value
Agency product number EMEA/H/C/000414
Orphan designation No
Date First Approved 22-04-2002
Type Medicinal product subject to medical prescription
Marketing authorisation holder Bayer AG